gabexate has been researched along with Precancerous Conditions in 2 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniluk, J | 1 |
| Liu, Y | 1 |
| Deng, D | 1 |
| Chu, J | 1 |
| Huang, H | 1 |
| Gaiser, S | 1 |
| Cruz-Monserrate, Z | 1 |
| Wang, H | 1 |
| Ji, B | 1 |
| Logsdon, CD | 1 |
| Douglas, BR | 1 |
| Woutersen, RA | 1 |
| Jansen, JB | 1 |
| de Jong, AJ | 1 |
| Rovati, LC | 1 |
| Lamers, CB | 1 |
2 other studies available for gabexate and Precancerous Conditions
| Article | Year |
|---|---|
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Ceruletide; Cyclooxygenase 2 | 2012 |
Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
Topics: Animals; Azaserine; Cholecystokinin; Esters; Gabexate; Glutamine; Guanidines; Male; Pancreatic Neopl | 1989 |